A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 54
- Registration Number
- NCT02254538
Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus Infection
Phase 1
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: PlaceboDrug: BILB 1941 ZW
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2014-10-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 96
- Registration Number
- NCT02254707
Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02254005
The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02254148
- Locations
- π©πͺ
1307.19.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 21
- Registration Number
- NCT02253836
Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BILR 355 - D1Drug: BILR 355 - D2Drug: BILR 355 - D3Drug: BILR 355 - D4Other: high fat breakfast
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT02253927
Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BEA 2180 BR - rising doseDrug: Placebo
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02254109
Pharmacokinetics of Single Doses of BILR 355 BS Given With Ritonavir in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BILR 355 BS, D8Drug: BILR 355 BS, D5Drug: BILR 355 BS, D7Drug: BILR 355 BS, D1Drug: BILR 355 BS, D3Drug: BILR 355 BS, D4Drug: BILR 355 BS, D6Drug: BILR 355 BS, D2Drug: PlaceboDrug: BILR 355 BS, D10Other: high-fat breakfast
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 62
- Registration Number
- NCT02253953
Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male Subjects
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2014-10-01
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT02253797
Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8
- Registration Number
- NCT02254031
Β© Copyright 2025. All Rights Reserved by MedPath